Head to Head Comparison: Sonic Healthcare (OTCMKTS:SKHHY) & BioNexus Gene Lab (NASDAQ:BGLC)

BioNexus Gene Lab (NASDAQ:BGLC) and Sonic Healthcare (OTCMKTS:SKHHY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Risk & Volatility

BioNexus Gene Lab has a beta of 5.31, suggesting that its stock price is 431% more volatile than the S&P 500. Comparatively, Sonic Healthcare has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioNexus Gene Lab and Sonic Healthcare”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.51 million	1.14	-$1.60 million	N/A	N/A
Sonic Healthcare	$5.94 billion	1.17	$337.11 million	N/A	N/A

Sonic Healthcare has higher revenue and earnings than BioNexus Gene Lab.

Profitability

This table compares BioNexus Gene Lab and Sonic Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-30.70%	-35.54%	-29.08%
Sonic Healthcare	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioNexus Gene Lab and Sonic Healthcare, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	0	0	0	0	0.00
Sonic Healthcare	0	0	1	0	3.00

Sonic Healthcare has a consensus target price of $30.15, indicating a potential upside of 114.74%. Given Sonic Healthcare’s stronger consensus rating and higher probable upside, analysts clearly believe Sonic Healthcare is more favorable than BioNexus Gene Lab.

Institutional and Insider Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 0.0% of Sonic Healthcare shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sonic Healthcare beats BioNexus Gene Lab on 9 of the 12 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Sonic Healthcare

Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.